BCB
CYCN icon

Brian C. Broderick’s Cyclerion Therapeutics CYCN Stock Holding History

Brian C. Broderick’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,609
Closed -$99K – 78
2021
Q3 		$99K Hold
1,609
– – 0.03% 80
2021
Q2 		$126K Hold
1,609
– – 0.03% 80
2021
Q1 		$90K Hold
1,609
– – 0.03% 79
2020
Q4 		$98K Hold
1,609
– – 0.03% 77
2020
Q3 		$196K Hold
1,609
– – 0.06% 84
2020
Q2 		$190K Hold
1,609
– – 0.06% 81
2020
Q1 		$86K Hold
1,609
– – 0.03% 76
2019
Q4 		$88K Sell
1,609
-37
-2% -$3.46K 0.03% 85
2019
Q3 		$399K Hold
1,646
– – 0.14% 65
2019
Q2 		$377K Buy
+1,646
New +$466K 0.13% 64

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brian C. Broderick's CYCN Position: Q4 2021 in Review

Brian C. Broderick sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 1,609 shares — an estimated $99K sold.

Brian C. Broderick first reported a position in CYCN in Q2 2019 and held it in 10 quarters. The position peaked at $399K in Q3 2019. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • Brian C. Broderick reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Brian C. Broderick sold 1,609 Cyclerion Therapeutics shares in Q4 2021, an estimated $99K.
  • Brian C. Broderick first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 10 quarters.
  • Brian C. Broderick's Cyclerion Therapeutics position peaked at $399K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on Brian C. Broderick's 13F filing for Q4 2021, filed 8 Feb 2022.